Literature DB >> 22133983

Low-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged woman: a case report and literature review.

Ping-Tao Tseng1, Yu Lee, Ya-En Lin, Pao-Yen Lin.   

Abstract

Prolongation of the corrected QT interval (QTc) on the electrocardiography is an important clinical condition because it increases the risk of torsade de pointes, a medical emergency that can cause sudden cardiac death. QTc prolongation can be induced by many drugs, including antipsychotics and tricyclic antidepressants (TCAs). Compared with TCAs, use of selective serotonin reuptake inhibitors (SSRIs) was less likely to cause severe cardiac adverse effects. Escitalopram, one of the SSRIs, has shown significant antidepressant efficacy and well tolerability. Here, we present one female patient showing QTc prolongation induced by low-dose (5 mg/day) treatment of escitalopram for 2 days. The QTc returned to normal soon after discontinuation of escitalopram. Clinicians should be cautious about cardiac effects when using a SSRI, even in a low dose. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22133983     DOI: 10.1016/j.genhosppsych.2011.10.005

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  9 in total

1.  Considerations on safety concerns about citalopram prescribing.

Authors:  Robert D Sheeler; Michael J Ackerman; Elliott Richelson; Thomas K Nelson; Jeffrey P Staab; Eric G Tangalos; Lisa M Dieser; Julie L Cunningham
Journal:  Mayo Clin Proc       Date:  2012-09-24       Impact factor: 7.616

Review 2.  Impact of Age and Sex on QT Prolongation in Patients Receiving Psychotropics.

Authors:  Simon W Rabkin
Journal:  Can J Psychiatry       Date:  2015-05       Impact factor: 4.356

3.  Lack of relationship between plasma levels of escitalopram and QTc-interval length.

Authors:  Mar Carceller-Sindreu; Javier de Diego-Adeliño; Maria J Portella; Xavier Garcia-Moll; Maria Figueras; Aina Fernandez-Vidal; Josep M Queraltó; Dolors Puigdemont; Enric Álvarez
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-01-23       Impact factor: 5.270

Review 4.  Citalopram and cardiac toxicity.

Authors:  M J Cooke; W S Waring
Journal:  Eur J Clin Pharmacol       Date:  2012-09-21       Impact factor: 2.953

Review 5.  Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms.

Authors:  Gerrit Frommeyer; Lars Eckardt
Journal:  Nat Rev Cardiol       Date:  2015-07-21       Impact factor: 32.419

6.  Escitalopram block of hERG potassium channels.

Authors:  Yun Ju Chae; Ji Hyun Jeon; Hong Joon Lee; In-Beom Kim; Jin-Sung Choi; Ki-Wug Sung; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-09-18       Impact factor: 3.000

Review 7.  QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.

Authors:  Mehrul Hasnain; W Victor R Vieweg
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

8.  Clinical use of antidepressant therapy and associated cardiovascular risk.

Authors:  W Stephen Waring
Journal:  Drug Healthc Patient Saf       Date:  2012-08-17

9.  Risk of Ventricular Arrhythmia with Citalopram and Escitalopram: A Population-Based Study.

Authors:  Elena Qirjazi; Eric McArthur; Danielle M Nash; Stephanie N Dixon; Matthew A Weir; Akshya Vasudev; Racquel Jandoc; Lorne J Gula; Matthew J Oliver; Ron Wald; Amit X Garg
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.